Published in Gene Therapy Weekly, July 20th, 2006
According to a study from the United States, "Adenoviral vector-mediated gene therapy might have potential for long-term correction of the monogenic disease hemophilia A. In this study, we tested the efficacy of administering a helper-dependent adenoviral vector (HDV) designed for maximal liver-restricted canine factor VIII (cFVIII) expression on three out-bred hemophilia A dogs."
"Three FVIII-deficient animals from the University of North Carolina colony were injected with 1 x 1012 (Dog A), and 3 x...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.